Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio ...Middle East

PR Newswire - News
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio
- Exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio, the biotech investment firm - Targeting the KRW 146 trillion global autoimmune disease market with partner who has top global drug development...

Read More Details
Finally We wish PressBee provided you with enough information of ( Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio )

Apple Storegoogle play

Also on site :